{
  "pmcid": "9907679",
  "sha256": "859ba4d84426cf43c165751d9d43caa545d84a7ebef11faf8c236de3892809f0",
  "timestamp_utc": "2025-11-10T00:13:55.534564+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 11.201082519964505,
    "reading_ease": 33.7291659272405,
    "word_count": 245
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Programmed Intermittent Epidural Bolus Intervals for Labor Analgesia"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "double-blinded, randomised controlled trial included 100 nulliparous women"
      },
      "Participants": {
        "score": 2,
        "evidence": "100 nulliparous women with singleton pregnancies at ≥37 weeks gestation"
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomly assigned to one of five PIEB intervals (35, 40, 45, 50, or 55 minutes)"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study evaluated the optimal interval for programmed intermittent epidural bolus (PIEB) analgesia"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was effective analgesia, defined as no requirement for patient-controlled epidural analgesia (PCEA) during the first stage of labor."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "using sequentially numbered opaque envelopes"
      },
      "Blinding": {
        "score": 2,
        "evidence": "Blinding was maintained for patients and outcome assessors."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "100 nulliparous women"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "93 were analyzed per protocol"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The estimated PIEB intervals for 50% (EI50) and 90% (EI90) effectiveness were 52.5 (95% CI, 48.4–62.6) and 37.0 (95% CI, 28.4–40.9) minutes, respectively."
      },
      "Harms": {
        "score": 1,
        "evidence": "No severe adverse events were reported"
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "ChiCTR2100047291"
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified."
      }
    },
    "total_score": 21,
    "max_score": 25
  }
}